E Dunlap|B D Johnson - JoVE Visualize

Showing results (331-340 of 366) with videos related to

Pageof 37

Sort By:

Circulation|October 20, 2004

Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trialsJames B Young, Mark E Dunlap, Marc A Pfeffer, et al.

Medrxiv : the Preprint Server for Health Sciences|April 10, 2026

Genome-Wide Variations of End Motif in Cell-Free DNA Fragments Distinguish Immunotherapy Responders from Non-Responders in Head and Neck Cancer: A Multi-Institute Prospective StudyRavi Bandaru, Hailu Fu, Haizi Zheng, et al.

Heart (British Cardiac Society)|August 12, 2009

Psychotropic medication use and risk of adverse cardiovascular events in women with suspected coronary artery disease: outcomes from the Women's Ischemia Syndrome Evaluation (WISE) studyD S Krantz, K S Whittaker, J L Francis, et al.

Biochemical Pharmacology|March 23, 1999

Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785)C M Discafani, M L Carroll, M B Floyd, et al.

The Journal of Clinical Investigation|May 19, 2026

Genome-wide variation in cell-free DNA end motif entropy predicts immunotherapy response in head and neck cancerRavi Bandaru, Hailu Fu, Haizi Zheng, et al.

JACC. Heart Failure|December 31, 2016

Body Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes: Findings From the ASCEND-HF TrialAndrew P Ambrosy, Lukasz P Cerbin, Paul W Armstrong, et al.

Journal of Medicinal Chemistry|September 1, 2000

4-Anilino-6,7-dialkoxyquinoline-3-carbonitrile inhibitors of epidermal growth factor receptor kinase and their bioisosteric relationship to the 4-anilino-6,7-dialkoxyquinazoline inhibitorsA Wissner, D M Berger, D H Boschelli, et al.

Oral Oncology|March 9, 2019

A competing risk nomogram to predict severe late toxicity after modern re-irradiation for squamous carcinoma of the head and neckMatthew C Ward, Nancy Y Lee, Jimmy J Caudell, et al.

Eclinicalmedicine|October 23, 2025

Avasopasem manganese treatment for severe oral mucositis from chemoradiotherapy for locally advanced head and neck cancer: phase 3 randomized controlled trial (ROMAN)Carryn Anderson, Christopher M Lee, Joseph Randall Kelley, et al.

Oral Oncology|February 20, 2022

Influence of Treatment Package Time on outcomes in High-Risk Oral Cavity Carcinoma in patients receiving Adjuvant Radiation and Concurrent Systemic Therapy: A Multi-Institutional Oral Cavity Collaborative studyAhmed I Ghanem, Neil M Woody, Mathew A Schymick, et al.

Pageof 37

Showing results (331-340 of 366) with videos related to

Sort By:

Pageof 37

Circulation|October 20, 2004

Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trialsJames B Young, Mark E Dunlap, Marc A Pfeffer, et al.

Medrxiv : the Preprint Server for Health Sciences|April 10, 2026

Genome-Wide Variations of End Motif in Cell-Free DNA Fragments Distinguish Immunotherapy Responders from Non-Responders in Head and Neck Cancer: A Multi-Institute Prospective StudyRavi Bandaru, Hailu Fu, Haizi Zheng, et al.

Heart (British Cardiac Society)|August 12, 2009

Psychotropic medication use and risk of adverse cardiovascular events in women with suspected coronary artery disease: outcomes from the Women's Ischemia Syndrome Evaluation (WISE) studyD S Krantz, K S Whittaker, J L Francis, et al.

Biochemical Pharmacology|March 23, 1999

Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785)C M Discafani, M L Carroll, M B Floyd, et al.

The Journal of Clinical Investigation|May 19, 2026

Genome-wide variation in cell-free DNA end motif entropy predicts immunotherapy response in head and neck cancerRavi Bandaru, Hailu Fu, Haizi Zheng, et al.

JACC. Heart Failure|December 31, 2016

Body Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes: Findings From the ASCEND-HF TrialAndrew P Ambrosy, Lukasz P Cerbin, Paul W Armstrong, et al.

Journal of Medicinal Chemistry|September 1, 2000

4-Anilino-6,7-dialkoxyquinoline-3-carbonitrile inhibitors of epidermal growth factor receptor kinase and their bioisosteric relationship to the 4-anilino-6,7-dialkoxyquinazoline inhibitorsA Wissner, D M Berger, D H Boschelli, et al.

Oral Oncology|March 9, 2019

A competing risk nomogram to predict severe late toxicity after modern re-irradiation for squamous carcinoma of the head and neckMatthew C Ward, Nancy Y Lee, Jimmy J Caudell, et al.

Eclinicalmedicine|October 23, 2025

Avasopasem manganese treatment for severe oral mucositis from chemoradiotherapy for locally advanced head and neck cancer: phase 3 randomized controlled trial (ROMAN)Carryn Anderson, Christopher M Lee, Joseph Randall Kelley, et al.

Oral Oncology|February 20, 2022

Influence of Treatment Package Time on outcomes in High-Risk Oral Cavity Carcinoma in patients receiving Adjuvant Radiation and Concurrent Systemic Therapy: A Multi-Institutional Oral Cavity Collaborative studyAhmed I Ghanem, Neil M Woody, Mathew A Schymick, et al.

Pageof 37